PMID- 31296820
OWN - NLM
STAT- MEDLINE
DCOM- 20190829
LR  - 20190829
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 46
IP  - 7
DP  - 2019 Jul
TI  - Clinical Evaluation of the Efficacy and Safety of Anagrelide Used with or without 
      Hydroxycarbamide in Japanese Patients with Essential Thrombocythemia-A 
      Retrospective Single-Center Study of 35 Cases.
PG  - 1141-1150
AB  - OBJECTIVE: The clinical features(CF), laboratory data, disease transformation 
      pattern and drug metabolism in essential thrombocythemia(ET)differ between Japan 
      and Western countries. The CF of ET in clinical practice(CP)are more diverse than 
      in prospective clinical studies. We should conduct retrospective analyses in CP. 
      The present study was aimed at evaluating the efficacy, safety and tolerability 
      of anagrelide(ANA)monotherapy and combined ANA plus hydroxycarbamide(HC)in 
      Japanese ET. PATIENTS AND METHODS: We have a total of 35 cases. Sixteen patients 
      received ANA monotherapy, 10 received ANA plus HC, and 9 received ANA plus other 
      drugs. RESULTS: Comparison among three groups revealed the absence of differences 
      in response rate(platelet count C60x10 / / 4/mL, platelet count 
      C40x104/mL)(43.8%, 6.3% vs. 50.0%, 10.0% vs. 44.4%, 11.1%), treatment 
      continuation rate(81.3% vs. 40.0% vs. 55.6%), median daily dose of ANA(1.00 mg in 
      all three groups)or median treatment period(days)(259 vs. 198.5 vs. 161.0), the 
      treatment continuation rate tended to be lower in the combined ANA plus HC. The 
      incidence of all adverse events(AEs)was higher in the ANA monotherapy(45.7%)than 
      ANA plus HC(28.6%)or ANA plus other drugs(25.7%), the AEs were mild in all 
      groups. CONCLUSION: The tolerability of ANA monotherapy, ANA plus HC, and ANA 
      plus other drugs were good.
FAU - Sekiguchi, Yasunobu
AU  - Sekiguchi Y
AD  - Dept. of Hematology, Juntendo University Urayasu Hospital.
FAU - Wakabayashi, Mutsumi
AU  - Wakabayashi M
FAU - Takizawa, Haruko
AU  - Takizawa H
FAU - Iizuka, Hiroko
AU  - Iizuka H
FAU - Sakajiri, Sakura
AU  - Sakajiri S
FAU - Sugimoto, Keiji
AU  - Sugimoto K
FAU - Inano, Tadaaki
AU  - Inano T
FAU - Fukuda, Yasutaka
AU  - Fukuda Y
FAU - Hamano, Yasuharu
AU  - Hamano Y
FAU - Tomita, Shigeki
AU  - Tomita S
FAU - Izumi, Hiroshi
AU  - Izumi H
FAU - Okubo, Mitsuo
AU  - Okubo M
FAU - Nakamura, Noriko
AU  - Nakamura N
FAU - Sawada, Tomohiro
AU  - Sawada T
FAU - Noguchi, Masaaki
AU  - Noguchi M
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 0 (Quinazolines)
RN  - K9X45X0051 (anagrelide)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Humans
MH  - Hydroxyurea/*therapeutic use
MH  - Japan
MH  - Quinazolines/*adverse effects
MH  - Retrospective Studies
MH  - *Thrombocythemia, Essential/drug therapy
EDAT- 2019/07/13 06:00
MHDA- 2019/08/30 06:00
CRDT- 2019/07/13 06:00
PHST- 2019/07/13 06:00 [entrez]
PHST- 2019/07/13 06:00 [pubmed]
PHST- 2019/08/30 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2019 Jul;46(7):1141-1150.